Lomond Therapeutics Holdings, Inc. financial data

Industry
Pharmaceutical Preparations
Location
C/O Lomond Therapeutics Holdings, Inc., 8 The Green Ste 8490, Dover, DE
State of incorporation
DE
Fiscal year end
December 31
Former names
Venetian-1 Acquisition Corp. (to 10/28/2024)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 65.7 %
Debt-to-equity 25.2 %
Return On Equity 1.87 % -99%
Return On Assets -1.55K % -12.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.2M shares +544%
Common Stock, Shares, Outstanding 27.2M shares +3484%
Entity Public Float 0 USD
Common Stock, Value, Issued 2.72K USD +3479%
Weighted Average Number of Shares Outstanding, Basic 5.18M shares +582%
Weighted Average Number of Shares Outstanding, Diluted 5.18M shares +582%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.94M USD +9308%
Operating Income (Loss) -11K USD -0.76%
Net Income (Loss) Attributable to Parent -11K USD -0.76%
Earnings Per Share, Basic -3.3 USD/shares +74.8%
Earnings Per Share, Diluted -3.3 USD/shares +74.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.4M USD
Assets, Current 2.27K USD +13.7%
Assets 2.27K USD +13.7%
Liabilities, Current 2.55M USD +198%
Liabilities 5.5M USD +542%
Retained Earnings (Accumulated Deficit) -38.8M USD -78.7%
Stockholders' Equity Attributable to Parent 23.8M USD
Liabilities and Equity 2.27K USD +13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -591 USD +94.4%
Net Cash Provided by (Used in) Financing Activities 15K USD -13.7%
Common Stock, Shares Authorized 300M shares +1479%
Common Stock, Shares, Issued 27.2M shares +3484%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.92K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.27K USD +13.7%
Deferred Tax Assets, Valuation Allowance 11.1M USD +65.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 11.1M USD +65.5%
Deferred Tax Assets, Operating Loss Carryforwards 3.36M USD +53.9%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 66.6M USD +311%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%